The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Authors
Keywords
Programmed death-1 receptor (PD-1), Programmed death ligand 1 (PD-L1), Cytotoxic T lymphocyte associated antigen-4 (CTLA-4), Tumor microenvironment (TME), Immune checkpoint inhibitor (ICI), Treatment-related adverse events (TRAEs), Mismatch repair, Microsatellite instability (MSI)
Journal
CLINICAL IMMUNOLOGY
Volume 226, Issue -, Pages 108707
Publisher
Elsevier BV
Online
2021-03-01
DOI
10.1016/j.clim.2021.108707
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer
- (2021) Keywan Mortezaee JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY
- Steps in metastasis: an updated review
- (2021) Jamal Majidpoor et al. MEDICAL ONCOLOGY
- Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma
- (2021) Zoe X. Malchiodi et al. Cancers
- Enhancing global access to cancer medicines
- (2020) Javier Cortes et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE‐100
- (2020) Shin Nishio et al. CANCER SCIENCE
- Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
- (2020) Ami N Shah et al. Journal for ImmunoTherapy of Cancer
- The Risk Ratio of Immune-Related Colitis, Hepatitis, and Pancreatitis in Patients With Solid Tumors Caused by PD-1/PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
- (2020) Yuan Tian et al. Frontiers in Oncology
- Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
- (2020) Myriam Chalabi et al. NATURE MEDICINE
- The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis
- (2020) Adile Orhan et al. EUROPEAN JOURNAL OF CANCER
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- (2020) Susan M Domchek et al. LANCET ONCOLOGY
- Prostate cancer reactivates developmental epigenomic programs during metastatic progression
- (2020) Mark M. Pomerantz et al. NATURE GENETICS
- Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow
- (2020) Johanna M. Buschhaus et al. ONCOGENE
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
- (2020) Manuela Terranova-Barberio et al. Nature Communications
- Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma
- (2020) Hee Seung Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Redox tolerance and metabolic reprogramming in solid tumors
- (2020) Keywan Mortezaee CELL BIOLOGY INTERNATIONAL
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer
- (2019) Mary L. Disis et al. JAMA Oncology
- The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis
- (2019) Yan Li et al. Frontiers in Pharmacology
- Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study)
- (2019) Janneke Hoogstad-van Evert et al. MEDICINE
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
- (2019) Vicky Makker et al. LANCET ONCOLOGY
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
- (2019) Kyung Hae Jung et al. CLINICAL CANCER RESEARCH
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
- (2019) M D Hellmann et al. ANNALS OF ONCOLOGY
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer – clinical results and biomarker analysis of GeparNuevo study
- (2019) S Loibl et al. ANNALS OF ONCOLOGY
- Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study
- (2019) U A Matulonis et al. ANNALS OF ONCOLOGY
- Extracellular‐signal‐regulated kinase (ERK)/mitogen‐activated protein kinase (MAPK) signaling as a target for cancer therapy: An updated review
- (2019) Masoud Najafi et al. CELL BIOLOGY INTERNATIONAL
- Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer
- (2019) Michael A. Morse et al. ONCOLOGIST
- Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study
- (2019) Lin Wang Journal of Ovarian Research
- Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance
- (2019) Simon Pernot et al. Gastric Cancer
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial
- (2019) Donald T. Weed et al. Frontiers in Immunology
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. CLINICAL CANCER RESEARCH
- Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers
- (2019) Joyce F. Liu et al. GYNECOLOGIC ONCOLOGY
- Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy relevance
- (2019) Masoud Najafi et al. LIFE SCIENCES
- A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
- (2019) Michal Bassani-Sternberg et al. Frontiers in Immunology
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study
- (2019) Devalingam Mahalingam et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer
- (2019) Ashley E. Ross et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Interval breast cancer is associated with other types of tumors
- (2019) Felix Grassmann et al. Nature Communications
- CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration
- (2019) Khanh T.P. Nguyen et al. CELLULAR SIGNALLING
- Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1α and HIF-2α
- (2019) Keywan Mortezaee LIFE SCIENCES
- Stromal reprogramming: A target for tumor therapy
- (2019) Masoud Najafi et al. LIFE SCIENCES
- Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer
- (2018) Michael C. Haffner et al. AMERICAN JOURNAL OF PATHOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
- (2018) Julius Strauss et al. CLINICAL CANCER RESEARCH
- Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma
- (2018) Lingyu Li et al. CYTOTHERAPY
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- Clinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma
- (2018) Jun Nakashima et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
- (2018) Karin M. Knudson et al. OncoImmunology
- Cancer-associated fibroblasts: Secretions, interactions, and therapy
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming
- (2018) Rajeev Mishra et al. JOURNAL OF CLINICAL INVESTIGATION
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
- (2018) Youn H Kim et al. LANCET ONCOLOGY
- Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
- (2018) Gemma A. Foulds et al. Frontiers in Immunology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
- (2018) Jason M. Redman et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma
- (2018) Adrienne A. Phillips et al. HAEMATOLOGICA
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
- (2018) Benjamin L. Maughan et al. ONCOLOGIST
- NSD2 is a conserved driver of metastatic prostate cancer progression
- (2018) Alvaro Aytes et al. Nature Communications
- Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors
- (2018) Miguel Sampedro-Núñez et al. Scientific Reports
- PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
- (2018) Fernando Concha-Benavente et al. Cancer Immunology Research
- Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer
- (2017) Yoshitaro Shindo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer
- (2017) Shuzhen Liang et al. MOLECULAR IMMUNOLOGY
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX–Bevacizumab Drug Treatment Regimen
- (2016) Emeric Limagne et al. CANCER RESEARCH
- The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review
- (2016) Xinxin Zhu et al. GYNECOLOGIC ONCOLOGY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
- (2016) Chunwan Lu et al. OncoImmunology
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma
- (2014) Svetlana Karakhanova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
- (2014) E. R. Lutz et al. Cancer Immunology Research
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started